Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
May 15
Show Filter
08:00 - 08:50 50 mins
Registration
08:50 - 09:00 10 mins
Opening remarks from the Chairperson
  • Mélanie Thill-Tayara - Antitrust/Competition Partner, Dechert LLP, France
09:40 - 10:40 60 mins
Info
INTERACTIVE DISCUSSION FORUM: Reverse payment patent settlements
  • David Hull - Partner, Van Bael & Bellis, Belgium
  • Ingrid Vandenborre - Partner, Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates, Belgium
  • Brian Sher - Partner, CMS, UK
  • Ann Pope - Senior Director (Antitrust), Competition and Markets Authority, UK
  • Latest developments and lessons learnt including but not limited to the following case law: Lundbeck and Servier
  • What are the lessons learnt from originator and generics companies?
10:40 - 11:10 30 mins
Morning coffee and networking break
11:10 - 12:10 60 mins
Info
CASE LAW ROUNDUP: Excessive pricing, discounts and rebates in the pharmaceutical industry
  • James Killick - Partner, White & Case LLP, Belgium
  • Ingrid Vandenborre - Partner, Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates, Belgium
  • Jacob Westin - Legal Counsel, Shire, Sweden
  • Current status of abusive dominance through excessive pricing in the pharmaceutical industry
  • Decisions and developments including but not limited to the following case law: Aspen, Pfizer, Flynn Pharma
  • Examining approaches NCAs are taking
  • Reviewing decisions on pricing and rebates
12:10 - 12:50 40 mins
Info
Recent EU merger control cases in the pharmaceutical industry
  • Rositsa Pencheva - Case Handler, DG Competition, European Commission, Belgium
  • Miranda Cole - Partner, Covington & Burling, Belgium
  • Satyen Dhana - Partner, Simmons & Simmons
  • Reviewing latest high profile cases
  • EU Commission’s innovation theory of harm
  • Exploring the key issues and pitfalls
  • Future developments
12:50 - 14:20 90 mins
Networking lunch
14:20 - 14:55 35 mins
Info
Off-label use and drug repurposing in the EU: competition law considerations
  • Andrea Bazzotti - Senior Legal Advisor, Celgene International, Switzerland
  • Opportunities and concerns for off-label use
  • Reimbursement policies for off-label use including Italian and French legislation
14:55 - 15:30 35 mins
Info
Examining parallel trade: Imports and exports
  • Maarten Meulenbelt - Partner, SIDLEY AUSTIN LLP, Brussels
  • Update on the Spanish dual pricing system and related case law
  • National responses to parallel trade-driven shortages
  • Jurisdiction of competition authorities
15:30 - 16:00 30 mins
Afternoon Coffee and Networking
16:00 - 17:30 90 mins
Info
INTERACTIVE DISCUSSION FORUM: Lifecycle management with respect to competition law, patents and regulatory frameworks
  • Claudia Desogus - Officer, Italian Antitrust Authority, Italian Competition Authority
  • Kyriakos Fountoukakos - Partner, Herbert Smith Freehills LLP, Belgium
  • Glyn Truscott - Partner – UK & European Patent Attorney, Elkington + Fife, UK
  • Livia Zamfiropol - Partner, DLA Piper, Romania
  • Roche/Novartis case
  • Pfizer case in Italy: The notion of abuse of rights
  • How can you use IP legitimately and not fall foul?
  • Avoiding pitfalls with IP and regulatory strategies
17:30 - 17:35 5 mins
Chair's closing remarks and end of competition day
18:15 - 20:15 120 mins
Info
EVENING SEMINAR A: Brexit: Implications for the Pharmaceutical Industry
  • Anneli Howard - Barrister, Monckton Chambers, UK
  • Peter Bogaert - Partner, Covington & Burling LLP, Belgium
  • Natasha Pearman - Managing Associate, Mishcon de Reya LLP, UK
  • Jonathan Mogford - Director of Policy, MHRA, UK

18:15 Registration • 18:30 Start • 20:15 Networking Dinner


Topics to be discussed will include:

  • Latest status and timelines for Brexit as of May 2018
  • Update on the relocation of the EMA and implications for industry
  • Discussing the impact of Brexit on:
  • Regulatory frameworks in the UK and across Europe
  • Pricing and reimbursement
  • Pharmacovigilance
  • Competition law obligations
  • Relocation of the UPC
  • A practical checklist approach for preparing for Brexit
Next Stream 1: Intellectual Property Stream 2: Regulatory Frameworks  Wednesday, 16 May 2018
This website uses cookies, including third party ones, to allow for analysis of how people use our website in order to improve your experience and our services. By continuing to use our website, you agree to the use of such cookies. Click here for more information on our Cookie Policy and Privacy Policy.